UK Biobank (core renewal)
Lead Research Organisation:
UK Biobank
Department Name: UNLISTED
Abstract
UK Biobank is supported by The Wellcome Trust, The National Institute of Health Research, The Medical Research Council, The British Heart Foundation and Cancer Research UK. The figures presented on this record represent the Medical Research Council funding contribution only with some additional UKRI Infrastructure funds in addition.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
Technical Summary
The UK Biobank resource has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. There are now sufficient numbers of incident cases of the commoner conditions to support extensive and powerful research into their determinants.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
Organisations
People |
ORCID iD |
Rory Collins (Principal Investigator) |
Publications
Schwartz R
(2022)
A Deep Learning Framework for the Detection and Quantification of Reticular Pseudodrusen and Drusen on Optical Coherence Tomography.
in Translational vision science & technology
Naito T
(2021)
A deep learning method for HLA imputation and trans-ethnic MHC fine-mapping of type 1 diabetes.
in Nature communications
Bi W
(2019)
A Fast and Accurate Method for Genome-wide Scale Phenome-wide G × E Analysis and Its Application to UK Biobank.
in American journal of human genetics
Bi W
(2020)
A Fast and Accurate Method for Genome-Wide Time-to-Event Data Analysis and Its Application to UK Biobank.
in American journal of human genetics
Zhong W
(2023)
A fast and powerful linear mixed model approach for genotype-environment interaction tests in large-scale GWAS.
in Briefings in bioinformatics
Zhou Y
(2020)
A Fast and Simple Method for Detecting Identity-by-Descent Segments in Large-Scale Data.
in American journal of human genetics
Garrido-Martín D
(2022)
A fast non-parametric test of association for multiple traits
Grinton B
(2022)
A founder event causing a dominant childhood epilepsy survives 800 years through weak selective pressure
in The American Journal of Human Genetics
Valluru MK
(2023)
A founder UMOD variant is a common cause of hereditary nephropathy in the British population.
in Journal of medical genetics
Williams DM
(2019)
A Frailty Index for UK Biobank Participants.
in The journals of gerontology. Series A, Biological sciences and medical sciences
Constantinescu AE
(2022)
A framework for research into continental ancestry groups of the UK Biobank.
in Human genomics
Jiang R
(2023)
A functional connectome signature of blood pressure in >30 000 participants from the UK biobank.
in Cardiovascular research
Sun B
(2022)
A gain-of-function mutation in the ITPR1 gating domain causes male infertility in mice.
in Journal of cellular physiology
Williams C
(2022)
A General Cognitive Ability Factor for the UK Biobank
Williams CM
(2023)
A General Cognitive Ability Factor for the UK Biobank.
in Behavior genetics
Jiang L
(2021)
A generalized linear mixed model association tool for biobank-scale data.
in Nature genetics
Legault MA
(2020)
A genetic model of ivabradine recapitulates results from randomized clinical trials.
in PloS one
Whitfield JB
(2022)
A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers.
in Journal of hepatology
Toh C
(2021)
A genetic risk score using human chromosomal-scale length variation can predict schizophrenia.
in Scientific reports
Kingsmore SF
(2022)
A genome sequencing system for universal newborn screening, diagnosis, and precision medicine for severe genetic diseases.
in American journal of human genetics
Lee KS
(2021)
A genome wide association study for lung function in the Korean population using an exome array.
in The Korean journal of internal medicine
Astiazaran-Symonds E
(2022)
A Genome-First Approach to Estimate Prevalence of Germline Pathogenic Variants and Risk of Pancreatic Cancer in Select Cancer Susceptibility Genes.
in Cancers
Ahmadmehrabi S
(2022)
A Genome-First Approach to Rare Variants in Dominant Postlingual Hearing Loss Genes in a Large Adult Population.
in Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
Meng W
(2020)
A genome-wide association study finds genetic variants associated with neck or shoulder pain in UK Biobank.
in Human molecular genetics
Kim SK
(2021)
A Genome-wide Association Study for Concussion Risk.
in Medicine and science in sports and exercise
Kim SK
(2021)
A genome-wide association study for shoulder impingement and rotator cuff disease.
in Journal of shoulder and elbow surgery
Huang Y
(2019)
A Genome-Wide Association Study for Susceptibility to Visual Experience-Induced Myopia
in Investigative Opthalmology & Visual Science
Sinkala M
(2023)
A genome-wide association study identifies distinct variants associated with pulmonary function among European and African ancestries from the UK Biobank.
in Communications biology
Casanova F
(2019)
A genome-wide association study implicates multiple mechanisms influencing raised urinary albumin-creatinine ratio.
in Human molecular genetics
Do A
(2022)
A genome-wide association study implicates the pleiotropic effect of NMUR2 on asthma and COPD
in Scientific Reports
Faber BG
(2023)
A Genome-Wide Association Study Meta-Analysis of Alpha Angle Suggests Cam-Type Morphology May Be a Specific Feature of Hip Osteoarthritis in Older Adults.
in Arthritis & rheumatology (Hoboken, N.J.)
Smit DJA
(2022)
A genome-wide association study of a rage-related misophonia symptom and the genetic link with audiological traits, psychiatric disorders, and personality.
in Frontiers in neuroscience
Atkins JL
(2021)
A genome-wide association study of the frailty index highlights brain pathways in ageing.
in Aging cell
Bhatt IS
(2022)
A genome-wide association study of tinnitus reveals shared genetic links to neuropsychiatric disorders.
in Scientific reports
Kim S
(2022)
A Genome-Wide Association Study Reveals Two Genetic Markers for Chondromalacia
in CARTILAGE
Zhu Z
(2018)
A genome-wide cross-trait analysis from UK Biobank highlights the shared genetic architecture of asthma and allergic diseases.
in Nature genetics
Skuladottir AT
(2022)
A genome-wide meta-analysis identifies 50 genetic loci associated with carpal tunnel syndrome.
in Nature communications
Bell S
(2021)
A genome-wide meta-analysis yields 46 new loci associating with biomarkers of iron homeostasis.
in Communications biology
Christou MA
(2020)
A genome-wide scan for pleiotropy between bone mineral density and nonbone phenotypes.
in Bone research
Dong G
(2021)
A global overview of genetically interpretable multimorbidities among common diseases in the UK Biobank.
in Genome medicine
Description | Impact of clinically silent atrial fibrillation on cerebrovascular disease and cognitive decline in the UK Biobank Imaging Cohort |
Amount | £2,474,260 (GBP) |
Funding ID | RG/18/6/33576 |
Organisation | British Heart Foundation (BHF) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 07/2019 |
End | 06/2024 |
Description | UK Biobank - The Repeat Imaging Project |
Amount | £2,500,000 (GBP) |
Funding ID | R39738/CN039 |
Organisation | MRC Dementias Platform UK |
Sector | Academic/University |
Country | United Kingdom |
Start | 04/2019 |
End | 01/2023 |
Description | UK Biobank - Whole genome sequencing of 50,000 UKB participants |
Amount | £30,000,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 03/2020 |
Description | UK Biobank- Expansion of the UKB imaging to a 4th centre and repeat imaging assessment of 10,000 participants |
Amount | £8,500,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 12/2022 |
Description | UK Biobank Scientific Conference |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | The UK Biobank Scientific Symposium included presentations about the successes and future plans of the UK Biobank. It took place on 21 June 2018 in London |
Year(s) Of Engagement Activity | 2018 |
Description | UK Biobank participant imaging event |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UK Biobank for participants of the imaging work |
Year(s) Of Engagement Activity | 2021 |
Description | UKBiobank participant events - 2014 - 2019 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UKB Biobank participants regularly attend events aimed at informing them about the work being undertaken with their data. Usually, the events last a few hours and include an overview from the chief scientist and two talks from scientists that have used UKB data. From 2014 - 2020 over 4,000 participants have taken part in events in Edinburgh (4), Manchester (4), Nottingham, Leeds, Cardiff (2), Newcastle (5), Glasgow (2), Bristol (2) and Reading(4). They are often over-subscribed and participants leave these events wishing to seek more information and support he programme in new ways (EG in imaging, genome sequencing) |
Year(s) Of Engagement Activity | 2014,2015,2016,2017,2018,2019 |
URL | http://www.ukbiobank.ac.uk |